^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
JIN-A04
i
Other names: JIN-A04
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
J Ints Bio, Yuhan Corp
Drug class:
HER2 inhibitor, HER2 exon 20 mutation inhibitor
Related drugs:
1year
JIN-A04, highly effective tyrosine kinase inhibitor targeting HER2 exon 20 insertion mutations in NSCLC (AACR 2023)
It was superior to Mobocertinib (IC50 = 27.1 nM for YVMA and IC50 = 3.3 nM for GSP) and comparable with Poziotinib (IC50 = 3.4 nM for YVMA and IC50 = 0.4 nM for GSP). JIN-A04 is highly potent against HER2 exon 20 insertion mutations including YVMA and GSP, while largely sparing HER2 WT activity. Also, JIN-A04 demonstrated effective HER2 pathway inhibition. Based on these robust activities for HER2 exon 20 insertion, JIN-A04 is expected to provide a potent therapeutic opportunity for NSCLC patients with HER2 exon20 insertion mutations.
HER2 exon 20
|
HER-2 (Human epidermal growth factor receptor 2)
|
EGFR mutation • HER-2 mutation • HER-2 expression • HER-2 exon 20 insertion • HER-2 A775_G776insYVMA • HER-2 exon 20 mutation • HER-2 A775 • HER-2 P780-Y781insGSP • HER-2 YVMA • HER-2 exon 23 mutation
|
Pozenveo (poziotinib) • Exkivity (mobocertinib) • JIN-A04
Share via
